CAMBREX LICENSES POWERFUL TECHNOLOGIES FOR CONDITIONALLY IMMORTALIZED CELLS FOR USE IN DRUG DISCOVERY

Cambrex has announced that its subsidiary Cambrex Bio Science Wokingham has signed an agreement for the purchase of conditionally immortalized cell lines, related intellectual property and equipment of Xcellsyz, Newcastle Upon Tyne, UK. Cambrex Bio Science Walkersville, also a subsidiary of Cambrex, has entered into license agreements for Geron's proprietary telomerase technology and complementary conditional immortalization technology from the Ludwig Institute for Cancer Research (LICR).

Yahoo News (http://biz.yahoo.com/prnews/050118/nytu048_1.html)